Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8533169 | 1.00 | OGA (0.32) | OGAABCB1 | |
| SCHEMBL11669546 | 1.00 | OGA (0.32) | OGAABCB1 | |
| SCHEMBL3207681 | 0.95 | OGA (0.34) | OGA | |
| SCHEMBL14312202 | 0.89 | ABCB1 (0.32) | OGAABCB1 | |
| SCHEMBL4617635 | 0.88 | ABCB1 (0.30) | ABCB1 | |
| SCHEMBL17004686 | 0.88 | — | — | |
| SCHEMBL812463 | 0.83 | ABCB1 (0.31) | ABCB1 | |
| SCHEMBL9452989 | 0.81 | ABCB1 (0.32) | ABCB1 | |
| SCHEMBL813499 | 0.81 | — | — | |
| SCHEMBL11759427 | 0.76 | OGA (0.41) | OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858773-B2 | Process for preparing substituted benzimidazole compounds | GLAXOSMITHKLINE LLC (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090187015-A1 | Process For Preparing Substituted Benzimidazole Compounds | GLAXOSMITHKLINE LLC | 2009-07-23 | — | — | US | disclosed |
| US-7514568-B2 | Process for preparing substituted benzimidazole compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-07 | — | — | US | disclosed |
| US-20080188668-A1 | PROCESS FOR PREPARING SUBSTITUTED BENZIMIDAZOLE COMPOUNDS | GLAXOSMITHKLINE LLC | 2008-08-07 | — | — | US | disclosed |
| US-7101994-B2 | Process for preparing substituted benzimidazole compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1584620-A1 | Process for preparing substituted benzimidazole compounds | GLAXO GROUP LIMITED (GB) | 2005-10-12 | — | — | EP | disclosed |
| EP-1272473-B1 | PROCESS FOR PREPARING SUBSTITUTED BENZIMIDAZOLE COMPOUNDS | GLAXO GROUP LTD (GB) | 2005-06-29 | — | — | EP | disclosed |
| US-20030191127-A1 | Process for preparing substituted benzimidazole compounds | GLAXOSMITHKLINE LLC | 2003-10-09 | — | — | US | disclosed |
| US-6617315-B1 | Sugar-substituted benzimidazole derivatives are used for the treatment or prophylaxis of restenosis, particularly following angioplasty | CHAMBERLAIN STANLEY DAWES (US) | 2003-09-09 | — | — | US | disclosed |
| US-6576620-B2 | Measuring agonist stimulated (35S)GTP gamma S binding to G proteins by compound, measuring extent of agonist stimulated (35S)GTP gamma S binding to G proteins by a full adenosine A1 receptor agonist, selecting compounds with 65-95% binding | CV THERAPEUTICS, INC. | 2003-06-10 | — | — | US | disclosed |
| US-20010003744-A1 | Therapeutic compounds | CHAMBERLAIN STANLEY DAWES (US) | 2001-06-14 | — | — | US | disclosed |
| WO-2001040245-A1 | N6 HETEROCYCLIC 5' MODIFIED ADENOSINE DERIVATIVES | CV THERAPEUTICS, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001040244-A1 | N6 HETEROCYCLIC 5' MODIFIED ADENOSINE DERIVATIVES | CV THERAPEUTICS, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001040799-A2 | METHOD OF IDENTIFYING PARTIAL ADENOSINE A1 RECEPTOR AGONISTS AND THEIR USE IN THE TREATMENT OF ARRHYTHMIAS | CV THERAPEUTICS, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| US-6204249-B1 | L-benzimidazole nucleosides | GLAXO WELLCOME INC. | 2001-03-20 | — | — | US | disclosed |
| US-6077832-A | FOR THERAPY AND PROPHYLAXIS OF HERPES VIRUS INFECTION | GLAXO WELLCOME INC. (US) | 2000-06-20 | — | — | US | disclosed |
| EP-0769017-B1 | THERAPEUTIC COMPOUNDS | WELLCOME FOUND (GB) | 2000-05-24 | — | — | EP | disclosed |
| US-5998605-A | Antiviral benzimidazole nucleoside analogues and method for their preparation | GLAXO WELLCOME INC. (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0769017-A1 | THERAPEUTIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-04-23 | — | — | EP | disclosed |
| WO-1996001833-A1 | THERAPEUTIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188668-A1 | PROCESS FOR PREPARING SUBSTITUTED BENZIMIDAZOLE COMPOUNDS | EIF2AK2, SAMHD1, ZC3HAV1 | OGA 1871/4885ABCB1 1237/4885 |
| US-20030191127-A1 | Process for preparing substituted benzimidazole compounds | EIF2AK2, SAMHD1, ZC3HAV1 | OGA 1871/4885ABCB1 1237/4885 |
| US-20010003744-A1 | Therapeutic compounds | ZC3HAV1, HAVCR2, EIF2AK2 | OGA 2691/4885ABCB1 358/4885 |
| US-20090187015-A1 | Process For Preparing Substituted Benzimidazole Compounds | EIF2AK2, SAMHD1, ZC3HAV1 | OGA 1871/4885ABCB1 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.